Evidence map›Paper›PMID 34745002›Full record

ArticleFrontiers in endocrinology2021

The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.

Zhiyu Xi, Pamela S Jones, Masaaki Mikamoto, Xiaobin Jiang, Alexander T Faje, Chuansheng Nie, Kathryn E Labelle, Yunli Zhou, Karen K Miller, Roy J Soberman and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Tumour microenvironment and pituitary tumour behaviour.Journal of endocrinological investigation · 2023
    Review
  7. Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023
    Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zhiyu XiNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Pamela S JonesDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Masaaki MikamotoDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Xiaobin JiangNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Alexander T FajeNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Chuansheng NieNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Kathryn E LabelleNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Yunli ZhouNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Karen K MillerNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Roy J SobermanNephrology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Xun ZhangNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Harvard University · USMassachusetts General Hospital · US

Funding

Leukotrienes and Lung InflammationR01AI068871 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SOBERMAN, ROY · 2007 to 2011
$2.5M
The Role of lncRNA MEG3 in Clinically Non-functioning Pituitary AdenomasR01CA193520 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SOBERMAN, ROY · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA193520NIAID NIH HHS R01 AI068871
6 · The paper itself

Abstract

Human pituitary adenomas are one of the most common intracranial neoplasms. Although most of these tumors are benign and can be treated medically or by transsphenoidal surgery, a subset of these tumors are fast-growing, aggressive, recur, and remain a therapeutic dilemma. Because antibodies against immune checkpoint receptors PD-1 and CLTA-4 are now routinely used for cancer treatment, we quantified the expression of mRNA coding for PD-1, CLTA-4, and their ligands, PD-L1, PD-L2, CD80, and CD86 in human pituitary adenomas and normal pituitary glands, with the ultimate goal of exploiting immune checkpoint therapy in aggressive pituitary adenomas. Aggressive pituitary adenomas demonstrated an increased expression of PD-L2, CD80, and CD86 in compared to that of normal human pituitary glands. Furthermore, aggressive pituitary tumors demonstrated significantly higher levels of CD80 and CD86 compared to non-aggressive tumors. Our results establish a rationale for studying a potential role for immune checkpoint inhibition therapy in the treatment of pituitary adenomas.

Indexed as

Tumor EscapeAdenomaBiomarkers, TumorCase-Control StudiesFemaleFollow-Up StudiesHumansImmune Checkpoint ProteinsMaleMiddle AgedNeoplasm Recurrence, LocalPituitary NeoplasmsPrognosisBiomarkers, TumorImmune Checkpoint Proteinsaggressive pituitary adenomaimmune checkpoint blockadeimmune escapeimmunotherapypituitary adenoma

Identifiers

PMID34745002
PMCPMC8566912
OpenAlexW3205872582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.